EP Wealth Advisors LLC Acquires 113 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

EP Wealth Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,275 shares of the biopharmaceutical company’s stock after purchasing an additional 113 shares during the quarter. EP Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,228,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Raymond James & Associates raised its stake in shares of Regeneron Pharmaceuticals by 8.9% in the fourth quarter. Raymond James & Associates now owns 66,999 shares of the biopharmaceutical company’s stock valued at $58,845,000 after acquiring an additional 5,499 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 4.5% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 8,772 shares of the biopharmaceutical company’s stock worth $7,704,000 after buying an additional 381 shares during the period. Pacer Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 15.0% in the 4th quarter. Pacer Advisors Inc. now owns 14,126 shares of the biopharmaceutical company’s stock worth $12,407,000 after buying an additional 1,845 shares during the period. Procyon Advisors LLC increased its stake in Regeneron Pharmaceuticals by 5.7% in the 4th quarter. Procyon Advisors LLC now owns 3,205 shares of the biopharmaceutical company’s stock worth $2,815,000 after buying an additional 174 shares during the period. Finally, Good Life Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $206,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial restated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,074.95.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $14.44 during trading on Friday, hitting $1,078.63. 380,897 shares of the stock traded hands, compared to its average volume of 386,591. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The company has a market cap of $118.85 billion, a price-to-earnings ratio of 31.86, a P/E/G ratio of 2.19 and a beta of 0.13. The company has a fifty day moving average price of $1,033.85 and a two-hundred day moving average price of $976.79. Regeneron Pharmaceuticals, Inc. has a 52-week low of $723.56 and a 52-week high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.36 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.